Medtronic’s tiny neurostimulator gets CE mark for multiple indications

Medtronic HQ
Medtronic's Intellis system earned FDA clearance in September for spinal cord stimulation.

Medtronic’s Intellis platform grabbed a CE mark for peripheral nerve and spinal cord stimulation. With the nod, the device is now cleared to treat chronic, intractable pain of the trunk, posterior trunk and limbs.

The Intellis system, which earned the FDA green light in September, is the world’s smallest fully implantable spinal cord stimulation neurostimulator, the company said. The system includes the implant, a patient programmer and a recharger. A physician programs the therapy wirelessly, using a Samsung tablet.

The device is designed to help physicians make better treatment decisions. In addition to delivering pain-relieving neurostimulation, it records patient activity, such as their body position and how they self-administer their treatment, around the clock.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Myoscience’s ‘cold therapy’ system bags FDA OK for knee pain

"Rather than rely on patient-reported data, the enhanced activity tracker of the Intellis platform provides real-time data that offers more visibility into quality of life changes," said Jean-Pierre Van Buyten of AZ Nikolaas Hospital in Belgium, where the first European patient received the implant. "Better understanding a patient's experience can lead to a more informed conversation that can help me maximize their pain relief.”

Non-opioid pain treatments are becoming increasingly important—the number of opioids prescribed and sold in the U.S. alone has quadrupled since 1999. While opioids used to be prescribed sparingly—after a surgery or injury, or for managing cancer-related pain—there has been a “dramatic increase” in their use for chronic, non-cancer pain, according to the CDC.

RELATED: Mebias' mu opioids best morphine, Trevena drug in preclinical studies

Some companies are developing painkilling drugs that do not have the same side effects as opioids, including dependence, constipation, nausea and sleepiness. On the device side, players like Medtronic and Abbott market neurostimulation treatments, with startups, such as SPR Therapeutics, trying to get a piece of the pie.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.